1. Komarov A. L. Recommendations for antitrombotic therapy for percutaneous coronary intervention. Atherothrombosis 2010; 1: 87–95. Russian (Комаров А. Л. Рекомендации по антитромботической терапии при чрескожных вмешательствах на коронарных артериях. Атеротромбоз 2010; 1: 87–95).
2. Mehta SR, Salim Y, Peters RSG, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI–CURE study. The Lancet 2001; 358: 527–33.
3. Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation N Engl J Med 2005; 352: 1179–89.
4. Steinhubl SR, Berger PB, Brennan DM, et al. Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention. JACC 2006; 47: 939–43).
5. Bhatt DL, Fox KAA, et al. Clopidogrel and Aspirin versus Aspirin A lone fore the Prevention of Atherothrombotic Events. N Engl J Med 2006; 354: 1706–17.
6. Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events afterclopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. JACC 2006; 48: 2584–91.
7. Pavlova TV, Dupliakov DV. Outstanding issues clopidpgrel with acute ischemic heart disease. Effective drug treatment in cardiology and angiology 2010; 2: 44–9. Russian (Павлова Т. В., Дупляков Д. В. Нерешенные вопросы применения клопидогрела при обострении ишемической болезни сердца. Эффективная фармакотерапия в кардиологии и ангиологии 2010; 2: 44–9).
8. Savi P, Combalbert J, Gaich C, et al. The antiaggregating activity of clopidogrel is due to a metabolic activation by the hepatic cytochrome P450–1A. Thromb Haemost 1994; 72 (2): 313–7.
9. Sumarokov AB, Burachkovskaya LB. The use of thienopyridines in patients with atherosclerotic lesions of the arteries. Guide for Physicians. Moscow 2012; 6–10. Russian (Сумароков А. Б., Л. Б. Бурячковская. Применение тиенопиридинов в лечении больных с атеросклеротическим поражением артерий. Руководство для врачей. Москва 2012; 6–10).
10. Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidpgrel responsiveness in healthy subjects. Blood 2008; 108: 2244–7.
11. Brandt JT, Close SL, Iturria SJ, et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007; 5: 2429–36.
12. Young-Hoon Jeong, MD, PHD,* In-Suk Kim, MD, PHD,† Yongwhi Park, MD, PHD,* et al. Carriage of Cytochrome 2C19 Polymorphism Is Associated With Risk of High Post-Treatment Platelet Reactivity on High Maintenance-Dose Clopidogrel of 150 mg/day Results of the ACCEL-DOUBLE. JACC 2010; 3 (7): 731–41.
13. Collet JP, Hulot JS, Anzaha G; High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2). JACС 2011; 4: 392–402.
14. Sawada T, Shinke T, Shite J, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 2011; 75 (1): 99–105.
15. Graciansky HA. Antiplatelet therapy for coronary heart disease. Some of the challenges and achievements. Atherothrombosis 2010; 1 (4): 2–52. Russian (Грац ианский Н. А. Антитромбоцитарная терапия при коронарной болезни сердца. Некоторые проблемы и достижения. Атеротромбоз 2010; 1 (4): 2–52).
16. Jneid H, Anderson JL, Wright RS, et al. 2012 ACCF/AHA focused update of the guideline for the management of patients UF/NSTEMI (updating the 2007 guideline and replacing the 2011 focused update): a report of the AACF/AHA Task Force on Practice Guidelines. Circulation 2012; 126: 875–910.
17. Wiviott SD, Braunwald E. Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes. N Engl J Med 2007; 357: 2001–15.
18. Yavelov IS. On the approach to the selection of antiplatelet agents for dual antiplatelet therapy for acute coronary syndrome. Clinical Pharmacology and Therapeutics 2012; 21 (3): 46–53. Russian (Явелов И. С. О подходах к выбору антиагрегантов для двойной антитромбоцитарной терапии острого коронарного синдрома. Клиническая фармакология и терапия 2012; 21 (3): 46–53).
19. Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010; 122: 2131–41.
